Hoofddorp, the Netherlands, 25 November 2021. IGEA Pharma N.V. (SIX: IGPH) receives an analyst vote. On Monday 22nd the research house GBC AG (www.gbc-ag.de/) publishes its first coverage equity research on the Company and from now on, GBC analysts Matthias Greiffenbergerand Felix Haugg will cover the further development of Igea Pharma NV with continuous assessment.
Press releases/News
GBC AG to start equity coverage of IGEA Pharma
Hoofddorp, the Netherlands, 04October 2021. IGEA Pharma N.V. (SIX: IGPH) today announced that GBCAG (www.gbc-ag.de/) will begin a full-coverage equity research on the Company.
IGEA discloses its half-2021 financials
Hoofddorp, the Netherlands, 30September 2021. IGEA Pharma N.V. (SIX: IGPH) todayannounced the disclosure of its half-2021 financials.
IGEA has been granted the listing of the new shares from SIX Exchange Regulation.
Hoofddorp, the Netherlands, 27September 2021. IGEA Pharma N.V. (SIX: IGPH) today announced that SIX Exchange Regulation AG (“SIX”) has granted the listing of 307’700’514 new registered shares with a nominal value of EUR 0.01 each out of authorized capital of IGEA Pharma NV, according to the International Reporting Standard of SIX Swiss Exchange.
IGEA to submit the listing prospectus to the SIX following the business combination with Blue Sky Natural Resources
Hoofddorp, the Netherlands, 06Septmeber 2021. IGEA Pharma N.V. (SIX: IGPH) today announced the application of the listing prospectus to the SIX Swiss Exchange Ltd (“SIX”) for the admission of the New IGEA Pharma Shares to trading. The New Shares to be listed in accordance with the International Reporting Standard of SIX will be exclusively issued to current shareholders of Blue Sky Natural Resources Ltd.
IGEA Pharma to boost revenues entering the growing cannabis market
Hoofddorp, the Netherlands, 2 August 2021. IGEA Pharma N.V. (SIX: IGPH) today announced revenue expectations over the next three years of CHF264 million globally, with an expected EBITDA margin in excess of 50% and expected net results of CHF126 million of the joint venture the Group will operate in the cannabis oil (CBD) market following the combination with Blue Sky Natural Resources Ltd (“BSNR”). The expected revenue stream from the joint venture of CHF63 million along with the additional EUR 4.5 million revenues from other segments will allow IGEA Pharma to be cash positive already by the end of 2022.
IGEA all equity offer to Blue Sky Natural Resources LTD now unconditional as to acceptances
Hoofddorp, the Netherlands, 26 July 2021. IGEA Pharma N.V. (SIX: IGPH) today announced that the all equity offer (the “Offer”) to Blue Sky Natural Resources Ltd is now unconditional as to acceptances.
IGEA announces Annual General Meeting resolutions
Hoofddorp, the Netherlands, 9 July 2021. IGEA Pharma N.V. (SIX: IGPH) today announced that its shareholders followed the recommendations of the company. The minutes of the general meeting is available at https://www.igeapharma.nl/category/information-for-shareholders/
IGEA to launch the all equity offer to Blue Sky Natural Resources Ltd.
Hoofddorp, the Netherlands, 30 June 2021. IGEA Pharma N.V. (SIX: IGPH) today announced the launch of the all equity offer (the “Offer”) to Blue Sky Natural Resources Ltd.
IGEA announces changes in its board and other corporate updates
Hoofddorp, the Netherlands, 3June 2021. IGEA Pharma N.V. (SIX: IGPH) today announced the resignation of Mrs. Rosanna Squitti and Mr. Giovanni Ferrario from its board of directors. Mr. Ferrario resigned for personal reasons and Mrs. Squitti left the corporate body for continuing to serve as Chief Scientific Officer of the Company. The Board furthermore elected Mrs. Giovanna Puppo as new Chairman, substituting Mr. Francesco Mario Patrocollo who will newly assume the role of vice Chairman.